Vitamin D following primary treatment of melanoma at high risk of recurrence (MelD)

Title: Vitamin D following primary treatment of melanoma at high risk of recurrence.  A blinded pilot placebo controlled randomised phase II trial.

Trial status: Open

Treatment type: Adjuvant

Stage of disease: IIb, IIc, IIIa(N1a), IIIb(N1a, N2a)

Intent of treatment: Prevention of recurrence

Lay Summary: Pilot study of 75 patients to assess the feasibility, safety and toxicity of oral vitamin D over a period of 2 years. Patients will be randomised to either receive active treatment or a placebo.

Target population is aged between18 – 79 years who have completed surgical treatment for their cutaneous malignant melanoma within 90 days and are considered to be at high risk for recurrence.


Contacts

Principal Investigator; Dr Robyn Saw

Trial Coordinator  -  Valerie Jakrot                 Tel: +61 2 9911 7306

Clinical Trials Manager  -  Sandie Grierson       Tel:  +61 2 9911 7301